Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 4Not yet recruiting 4Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1324Neoplasms 982Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 724Colorectal Neoplasms 666Lung Neoplasms 551Leukemia, Myeloid, Acute 475Neoplasm Metastasis 434Pancreatic Neoplasms 419Carcinoma, Hepatocellular 407Multiple Myeloma 396Ovarian Neoplasms 392Stomach Neoplasms 379Recurrence 364Squamous Cell Carcinoma of Head and Neck 325Melanoma 294Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Glioblastoma 264Head and Neck Neoplasms 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 234Lymphoma 228Rectal Neoplasms 222Esophageal Neoplasms 222Sarcoma 213Carcinoma, Renal Cell 203Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

trastuzumab deruxtecan 1pembrolizumab 1Trastuzumab 1Oxaliplatin 1Fluorouracil 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × HER2-positive Gastric Cancer × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06572319 2024-08-27

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Zhejiang Cancer Hospital

Phase 1/2 Recruiting
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡